Puma Biotechnology | PBYI - Cash And Equivalent


Puma Biotechnology reported $53.52M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Agios Pharmaceuticals USD 113.6M 24.47M Mar/2026
Alnylam Pharmaceuticals USD 1.71B 53.53M Mar/2026
Amgen USD 12.04B 2.91B Mar/2026
Biogen USD 3.38B 374.2M Mar/2026
BioMarin Pharmaceutical USD 2.22B 910.76M Mar/2026
Daiichi Sankyo JPY 542.16B 97.68B Sep/2025
Esperion Therapeutics USD 156.16M 11.69M Mar/2026
Exelixis USD 226.15M 256.34M Mar/2026
Gilead Sciences USD 7.56B 234M Dec/2025
Glaxosmithkline GBP 3.3B 303M Sep/2025
Incyte USD 4.02B 435.22M Mar/2026
MacroGenics USD 66.52M 9.3M Mar/2026
Moderna USD 1.91B 687M Mar/2026
Novartis USD 6.88B 4.56B Mar/2026
Pfizer USD 1.7B 561M Mar/2026
PTC Therapeutics USD 833.99M 150.66M Mar/2026
Puma Biotechnology USD 53.52M 1.14M Sep/2025
Regeneron Pharmaceuticals USD 2.96B 15.9B Mar/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Sarepta Therapeutics USD 464.45M 336.83M Mar/2026
Takeda JPY 654.94B 26.55B Dec/2025
TG Therapeutics USD 442.21M 242.7M Mar/2026
Ultragenyx Pharmaceutical USD 175M 246M Mar/2026
Vanda Pharmaceuticals USD 84.85M 14.83M Dec/2025
Vertex Pharmaceuticals USD 7.25B 638.6M Mar/2026